Possible Benefits of Metformin for Lung Cancer Still Unknown

Tyrosine kinase inhibitors (TKI) or monoclonal antibodies (mAb) for the Treatment of NRG1 and, Potentially, NRG2 Fusion–Positive Malignancies

Vemurafenib Alone and Combination for Lung Cancer: A Conversation with Marcelo V. Negrao, MD

Premonitions About Lung Cancer for the Next Decade 

Pyrotinib: A Potential New Anti-HER2 Therapy for Lung Cancer

Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Liquid Biopsy: The Key Weapon for Real-Time Monitoring of Patients With NSCLC 

PD-L1 Blockade Reinvigorates Dendritic Cells for Antitumor Immunity

Research’s Race to Stop a Pandemic